10 Mar Promega and EraGen sign technology licensing agreement
Madison, Wis. — Promega Corporation and EraGen Biosciences, two Madison-based life science companies, signed a licensing agreement Wednesday allowing Promega to develop products using EraGen’s research assays. The partnership also grants Promega global distribution rights for research assays.
“Promega should expect rapid market acceptance as validated by our recent SARS detection system. A market presence by Promega will further enhance EraGen’s product development for the clinical diagnostic market,” said Irene Hrusovsky, president and chief of operations of EraGen.
EraGen will provide its chemistry and software to analyze test results. Promega will develop and manufacture reagent systems in its Madison facility with the first branded product scheduled to be launched this year.
EraGen develops and commercializes molecular diagnostics. Promega provides technical support to the life sciences industry by combining chemistry and software.